secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001437749-26-015218
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica Q1 net loss $10M; cash $51.3M; ReMEDy2 >70% enrollment
----------------------------------------------------------------

- Net loss $10.0M in Q1 2026 vs $7.7M in Q1 2025; R&D expenses up to $8.0M from $5.7M.
- Cash $51.3M as of March 31, 2026, down from $59.9M; company expects runway through 2027.
- ReMEDy2 Phase 2/3 acute ischemic stroke trial surpassed 70% of required enrollment; interim analysis planned Q4 2026.
- Preeclampsia Phase 2 IST expansion cohort enrolling; updated dataset expected in Q2 2026.
- Rabbit study showed antibody response to DM199, preventing fetal development study; awaiting FDA response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774926015218/0001437749-26-015218-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774926015218/dmtp20260506_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-015218

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer